Adjuvant and salvage treatment after radical prostatectomy: Current practice in the UK

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 3, 2005, Pages 229-234

  Lee, L W ^a   Clarke, N W ^a   Ramani, V A C ^a   Cowan, R A ^a   Wylie, J P ^a   Logue, John P ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Prostatectomy; Radiation therapy; Salvage

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DRUG CHOICE; GLEASON SCORE; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SPECIALIST; ONCOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; RADIATION DOSE; SALVAGE THERAPY; SEMINAL VESICLE DISEASE; UNITED KINGDOM; UROLOGY;

CHEMOTHERAPY, ADJUVANT; GONADOTROPIN-RELEASING HORMONE; GREAT BRITAIN; HUMANS; MALE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIOTHERAPY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 31044434829     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500816     Document Type: Article

References (12)

1. Oliver SE et al. Recent trends in the use of radical prostatectomy in England: The epidemiology of diffusion. Br J Urol Int 2003; 91: 331-336.
2. Kupelian PA et al. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043-1052.
3. Anscher MS, Prosnitz LR. Multivariate analysis of factors predicting local relapse after radical prostatectomy-possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1991; 21: 941-947.
4. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999; 281: 1591-1597.
5. Ornstein DK et al. Evaluation and management of men whose radical prostatectomies failed: Results of an international survey. Urology 1998; 52: 1047-1054.
6. Johnstone PAS et al. Initiation of salvage therapy for prostate cancer. Pros Cancer Prosstatic Dis 2002; 5: 136-143.
7. Duchesne GM et al. What to do for prostate cancer patients with a rising PSA? A survey of Australian practice. Int J Radiat Oncol Biol Phys 2003; 55: 986-991.
8. Rodrigues G et al. Contemporary management of prostate cancer: A practice survey of Ontario genitourinary radiation oncologists. Radiat Oncol 2003; 69: 63-72.
9. See W et al. Immediate treatment with bicaltumide 150 mg as adjuvant treatment significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol 2003; 44: 512-517.
10. Messing E et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. N Eng J Med 1999; 341: 1781-1788.
11. Iversen P et al. Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004; 172: 1871-1876.
12. Bolla M et al. Post-operative radiotherapy after radical prostatectomy improves progression free survival in pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: S186 (abstr).